From Japan
to the World
From entrepreneurial beginnings to Global Healthcare Partner
For more than 70 years, NIPRO has evolved alongside the healthcare industry. Guided by entrepreneurship and a commitment to quality, we have continuously expanded our capabilities to help healthcare systems address changing and unmet needs and improve patient outcomes worldwide.
01
Our journey
A journey of continuous growth, built on our values and driven by the needs of healthcare systems around the world.
Establishment
NIPRO was founded in 1947 as a light bulb recycling business.
In 1954, Nihon Glass Shoji Co., Ltd. (current NIPRO CORPORATION) was established, and began marketing glass tubes for ampoules. Our products included not only medical glass but also small light bulbs and glass for vacuum flasks. The company also entered the supermarket business (later Nissho Store).
- 1947
- 1950
- 1954
- 1959
- 1960
- 1963
Our founder, Sano Minoru, was just 20 when he started a light bulb recycling business in Otsu, Shiga Prefecture, with the assistance of Biwako Natural Gas Co., Ltd.
Biwako Denkyu Seisakujo LLC was established in Otsu, Shiga Prefecture, and began trading with the Glass Section of NEC Corporation (later Nippon Electric Glass Co., Ltd.).
Nihon Glass Shoji Co., Ltd. was established in Shimogyo-Ku, Kyoto, and started selling glass tubes for ampoules and pill bottles.
Head office moved to Oyodo-Ku (current Kita-Ku), Osaka.
Otsu Factory (current Biwako Factory in Kusatsu, Shiga Prefecture) was built in Otsu, Shiga Prefecture, and started production of glass bottles and small light bulbs.
Automatic machines for processing inner flasks of vacuum flasks were developed, and the company began selling glass for vacuum flasks.
The company also entered the supermarket business.
Expansion into the Medical Industry
With the success of the glass and supermarket businesses, the company entered the medical industry through capital participation and corporate acquisition.
- 1965
- 1966
- 1969
- 1972
The company began selling infusion kits for pharmaceutical companies, starting its expansion into the medical device industry.
The company opened its Tokyo Business Office (current Technical Sales Department of the PharmaPackaging Division) in Chiyoda-Ku, Tokyo.
Tomisawa Manufacturing Co., Ltd. (current Nipro Medical Industries Co., Ltd.) was acquired, and production of medical devices started.
Nihon Plastic Specialties Co., Ltd. (corporate name changed to NIPRO Co., Ltd. in the same year) was purchased to handle domestic sales of medical devices.
Expansion into the Medical Business
In this period, NIPRO shifted its focus to the medical business, with an emphasis on dialyzers (artificial kidneys). At first, NIPRO manufactured coil dialyzers, and then was one of the first companies in Japan to begin manufacturing hollow fiber dialyzers. Since this time, the company has been serving the needs of many patients in need of hemodialysis. The company also opened the Technological Development Center (current NIPRO Creative innovation Center) in Kusatsu, Shiga Prefecture, and the Odate Factory in Odate, Akita Prefecture. This established the company as an integrated manufacturing system, from research and development through to production of medical devices.
- 1974
- 1975
- 1976
- 1977
- 1978
- 1981
- 1983
Nipro Medical Industries Co., Ltd. began manufacturing disposable syringes and coil dialyzers.
The company began manufacturing blood tubing, infusion kits, and hollow fiber dialyzers.
The company began manufacturing vacuum blood collection tubes and catheters.
The company changed its corporate name to Nissho Corporation. Technological Development Center (current NIPRO Creative innovation Center) was established in Kusatsu, Shiga Prefecture.
The company began the joint development of cellulose acetate hollow fiber membranes with a major material manufacturer.
NIPRO Odate Factory was built in Odate, Akita Prefecture.
The company began supplying dialyzers and related products to a major medical device distributor in the United States.
The company also started manufacturing medical rubber stoppers.
Expansion Overseas of the Medical Business and Launch of the Pharmaceutical Business
The quality and reliability of NIPRO’s medical devices were evaluated highly by overseas companies, and the company started to do business with companies all over the world. In 1988, the company established its first overseas manufacturing and marketing base in Thailand, thus embarking on the globalization of its business.
In addition, the company fully launched its pharmaceutical business to address increasing needs for kits combining pharmaceuticals and medical devices in clinical settings. This established the company’s three business pillars—medical devices, pharmaceuticals, and glass—that it has maintained to this day.
- 1984
- 1985
- 1986
- 1987
- 1988
- 1990
- 1991
The company began supplying insulin injection needles to a major pharmaceutical company in Denmark.
The company began supplying vacuum blood collection needles to a major medical device company in the United States.
The Japan-U.S. MOSS talks promoted the manufacture of medical device kits.
The company began supplying arteriovenous fistula (AVF) needles for dialysis to a major medical device company in Sweden.
The company was listed on the Second Section of the Osaka Securities Exchange.
The cellulose triacetate (CTA) dialyzer, an international commodity, was developed.
The company acquired capital in Hishiyama Pharmaceutical Corporation (current Nipro Pharma Corporation) to expand its business into pharmaceuticals.
Nissho Nipro Corporation (current Nipro (Thailand) Corporation Limited) was established in Thailand.
The company was designated on the First Section of the Osaka Securities Exchange.
Hishiyama Pharmaceutical Corporation Ise Plant (current Nipro Pharma Corporation Ise Plant) was constructed.
A full (integrated) kit of antibiotics was developed with a major pharmaceutical manufacturer.
Nissho Nipro Europe N.V. (current Nipro Medical Europe N.V.) was established in Belgium.
Expansion of Injection Kits
During this period, NIPRO accelerated its global business expansion by establishing business bases in quick succession, including locations in China, Brazil, the United States, and Singapore.
In 1996, the company was listed on the First Section of the Tokyo Stock Exchange. The company focused on the research and development of medical devices and pharmaceuticals, and also developed infusion kits in succession by combining its technologies.
- 1994
- 1995
- 1996
- 1997
- 1998
- 2001
- 2002
- 2003
The company acquired Hishiyama Pharmaceutical Corporation as a subsidiary. The company also launched half-type kits.
Nipro (Shanghai) Co., Ltd. was established in China.
The company launched integrated kits.
Nipro Medical Ltda. was established in Brazil.
Nipro Medical Corporation was established in the U.S.
The company was listed on the First Section of the Tokyo Stock Exchange.
The company launched sodium hyaluronate pre-filled syringes.
Nissho Nipro Asia Pte Ltd (current Nipro Asia Pte Ltd) was established in Singapore.
Pharmaceutical Research Center was constructed in Kusatsu, Shiga Prefecture.
The company acquired capital in Makino Pharmacy Co., Ltd. (corporate name changed to Nissho Drug Co., Ltd. in the same year).
The company changed its corporate name to NIPRO CORPORATION. Store Section was spun off to Nissho Corporation.
Hishiyama Pharmaceutical Corporation Odate Plant (current Nipro Pharma Corporation Odate Plant) was constructed.
The company began contract manufacturing of pre-filled syringes for dialysis.
Hishiyama Pharmaceutical Corporation changed its name to Nipro Pharma Corporation.
Nipro Trading (Shanghai) Co., Ltd. was established in China.
Focusing Resources on the Medical Field
NIPRO has been focusing its management resources on the medical field, and actively promoting capital investment, alliances, and M&A. By integrating the three technologies of medical devices, pharmaceuticals, and glass, the company has been making efforts to expand its product lineup and increase its share of the global market.
- 2004
- 2005
- 2006
- 2007
- 2008
- 2010
- 2011
- 2012
- 2013
- 2014
- 2015
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2025
The company acquired capital in Takeshima Pharmaceutical Corporation (current Nipro Pharma Corporation Saitama Site).
Apr : The company acquired the cardiopulmonary bypass section of Dainippon Ink and Chemicals, and fully entered into the oxygenator business.
June : The company acquired Tohoku Chugai Pharmaceutical Co., Ltd. (current Nipro Pharma Corporation Kagamiishi Plant) to expand its business to solid formulations.
Apr: The company acquired capital in Zensei Pharmaceutical Industries Co., Ltd.
Jul : The company transferred all shares of Nissho Corporation to Hankyu Department Stores, Inc.
Aug : The company acquired the cardiopulmonary bypass section of Edwards Lifesciences Corporation in the United States to promote the global expansion of the oxygenator business.
Oct : The company transferred the shares of Nissho Drug Co., Ltd. held by NIPRO to Kirindo Co., Ltd., clarifying its policy of concentrating its management resources on its core business (medical devices and pharmaceuticals).
May: The company acquired Saitama Daiichi Pharmaceutical Corporation (current Nipro Pharma Corporation Plant 2 and 3, Saitama Site) to expand its business to transdermal systems.
June: The company began integrated production, from the spinning of hollow fiber membranes to the production of dialyzers, at the Odate Factory.
Oct : The company developed partnerships with ReproCELL Inc. and Cell Science & Technology Institute, Inc. to develop joint business and expand the lineup of culture-medium-related products using ES/iPS cells and somatic stem cells.
Feb: Nipro India Corporation Private Limited and Nipro Glass India Pvt Ltd (current Nipro PharmaPackaging India Private Limited) were established in India.
Mar: The company acquired Home Diagnostics, Inc. (currently named Nipro Diagnostics, Inc.) in the United States as a subsidiary to expand its overseas diabetes-related business.
Sep: The company acquired capital in Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd. was established to expand its business to medical glass in China.
Oct: The company acquired capital in Nipro Medical (Hefei) Co., Ltd. to expand its business for the purpose of the production of medical devices in China.
Nov: The company acquired capital in Jilin Nipro Jiaheng Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
Jan: The company acquired capital in Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd. to expand its business to medical glass in China.
Feb: PT. NIPRO INDONESIA JAYA was established in Indonesia.
Mar: The company acquired JMI Company Ltd. (current Nipro JMI Company Ltd.) to expand its medical business in Bangladesh.
Apr: The company acquired Tube Glass Containers Ltd. (current Nipro PharmaPackaging India Private Limited) to expand its business to medical glass in India.
Jul: The company purchased medical glass business in France (current Nipro PharmaPackaging France S.A.S), Belgium (current Nipro PharmaPackaging Belgium N.V.), and the U.S. (current Nipro PharmaPackaging Americas Corp.) from Amcor Limited to expand its medical glass business.
Aug: The company acquired Nipro Pharma Glass AG, its holding company in Switzerland, to expand its medical glass business in Russia.
Jan: The company acquired JMI Pharma Ltd. (current Nipro JMI Pharma Ltd.) to launch its pharmaceutical business in Bangladesh.
Apr: The company purchased MGlas AG (current Nipro PharmaPackaging Germany GmbH) and MG Sterile Products AG (current Nipro PharmaPackaging Germany GmbH) to expand its medical glass business in Germany.
Mar: The company acquired Goodman Co., Ltd. (current Nipro Vascular Corporation) to enhance its cardiovascular business.
Jul: The company acquired capital in Infraredx, Inc. (current NIPRO Vascular Innovations Americas, Inc.) to expand its cardiovascular business in the U.S.
Dec: Nipro Amtes Co., Ltd. was established for production of medical electronic devices.
Mar: The company acquired Cell Science & Technology Institute, Inc. to enhance its cell culture business.
Jun: Biwako Factory was newly built in Kusatsu, Shiga Prefecture as a mother factory for glass business. Otsu Factory was transferred to the new factory.
Oct: The company opened NIPRO iMEP, a medical training facility, in Kusatsu, Shiga Prefecture.
Apr: The medical business of Unitika Ltd. was transferred to the company to enhance its test drug business.
Oct: The company acquired Infraredx, Inc. (current NIPRO Vascular Innovations Americas, Inc.) to enhance its cardiovascular business in the U.S.
Nipro PharmaPackaging (Shanghai) Co., Ltd. was established for the purpose of developing medical glass business in China.
Jan: The company transferred all shares of Nipro Diagnostics, Inc. to Sinocare, Inc. in China.
Jun: Nipro System Software Engineering Co., Ltd. (current Nipro Digital Technologies Co., Ltd.) was established for the purposes of development, manufacturing, and sales of systems such as medical software.
Dec: The company opened the Research and Development Center for Regenerative Medicine.
Jan: The company acquired NexMed International Co., Ltd. as a subsidiary to expand its orthopedics business.
Jan: The company acquired capital in Transonic Japan Co., Ltd. (current Nipro Transonic Co., Ltd.) to expand its orthopedics business.
Mar: The company established Nipro Vietnam Company Limited in Vietnam to manufacture medical devices.
Apr: Nipro Pharma Corporation absorbed Nipro Patch Co., Ltd.
Oct: The company acquired Tanabe Pharma Sales Co., Ltd. (current Nipro ES Pharma Co., Ltd.) as a subsidiary to expand the generic drugs of its own brand.
Feb: The company acquired Machida Endoscope Co., Ltd. as a subsidiary to expand its business to endoscope related business.
Apr: The company merged the sales organization of Goodman Co., Ltd. (current Nipro Vascular Corporation) with our Vascular Division to expand its vascular business.
Feb: Nipro (China) Holdings Co., Ltd was established to strengthen business management and efficient use of management resources in China.
Mar: Nipro Pharma Corporation purchased Kasukabe Plant (current Nipro Pharma Saitama Site) from Nihon Generic Co., Ltd.
Apr: Nipro Pharma Corporation acquired Tanabe Seiyaku Yoshiki Factory Co., Ltd. (current Nipro Pharma Hida Factory Corporation).
Apr: The company merged the sales organization of Nipro ES Pharma Co., Ltd. with our Domestic Division to expand its pharmaceutical business.
Jul: The company acquired JMI Syringes & Medical Devices Limited to enhance its medical business in Bangladesh.
Nov: The company acquired JMI Marketing (current NIPRO JMI Medical Ltd.) to enhance its medical business in Bangladesh.
Dec: The company acquired NephroFlow N.V. (current Nipro Digital Technologies Europe) to enhance its development of software for dialysis information management systems in Europe.
Dec: The company established Nipro Renal Solutions USA Corporation in the United States to manufacture dialytic fluid.
Mar: The company established Nipro Medical Morocco SARL in Morocco to strengthen sales of medical devices in Morocco and West Africa.
Jul: The company acquired MTN Neubrandenburg GmbH in Germany to enhance its dialytic fluid business in Germany and eastern Europe.
Apr: The company acquired Piramida d.o.o. (current Nipro PharmaPackaging Croatia LLC) in Croatia to enhance its manufacturing and sales of glass containers for medical use in central Europe.
Jul: The company established Nipro Sales Vietnam Limited for the purpose of selling medical equipment in Vietnam.
Aug: The company established Nipro Holding Americas, Inc.(current Nipro Americas Group Companies, Inc.)to strengthen management control of entities located in the Americas and to efficiently utilize management resources.
Dec: Nipro Medical Philippines Corp. was established to handle sales of medical devices and to provide an in-house dialysis center in the Philippines.
Apr: Following market classification revisions of the Tokyo Stock Exchange, the company was moved from the First Section to the Prime Market.
Apr: Head office functions were transferred to 3-26, Senriokashinmachi, Settsu, Osaka, Japan.
Apr: Participation in OSAKA Healthcare Pavilion at Expo 2025 Osaka, Kansai, Japan.
Click here for more details